The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.

Y, Zhao; L, Wu; Q, Lu; X, Gao; X, Zhu; X, Yao; L, Li; W, Li; Y, Ding; Z, Song; L, Liu; N, Dang; C, Zhang; X, Liu; J, Gu; J, Wang; S, Geng; Q, Liu; Y, Guo; L, Dong; H, Su; L, Bai; JT, O'Malley; J, Luo; E, Laws; L, Mannent; M, Ruddy; N, Amin; A, Bansal; T, Ota; M, Wang; J, Zhang

doi:10.1111/bjd.20690

Public

The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.

Shared by NobleBlocks on Oct 21, 2021 • 12:00 AM UTC

Authors:

Zhao Y

Wu L

Lu Q

Abstract

<h4>Background</h4>Dupilumab is an antibody against interleukin-4 receptor α, used in the treatment of atopic dermatitis (AD).<h4>Objectives</h4>To evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate-to-severe AD.<h4>Methods</h4>In this randomized, double-blind, pla...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!